인공광 이용형 식물공장에서 인공광원의 전력 소모는 작물 생산 비용을 증가시키는 주요한 요인이다. 따라서 인공광원의 광 이용효율을 향상시키는 것은 식물공장의 경제성 확보에 중요한 사안이다. 본 연구의 목적은 다양한 스펙트럼을 갖는 백색 LED와 원적색광을 추가한 다양한 백색 LED에서 재배 된 이고들빼기의 생산성과 광 이용효율을 비교하는 것이다. 파종 후 3주된 이고들빼기 묘는 심지 이용 수경재배 시스템에 정식되었고, 기온 20 ± 0.1°C, 상대습도 60 ± 0.1%, 이산화탄소 938.2 ± 5.8μmol·mol -1 , 광도 PPFD 250.6 ± 0.6μmol·m -2 ·s -1 , 광주기 16시간으로 설정된 인공광 이용형 식물공장에서 5주 재배되었다. 광질 처리조건은 대조구로 식물재배용 3가지 백색 LED(CL 1, CL 2, CL 3), 백색 LED 그룹[Warm W(WW), Neutral W(NW), Neutral W + Red(NWR), Cool W(CW)], 원적색광이 추가된 백색 LED 그룹(WWFR, NWFR, NWRFR, CWFR)이 사용되었다. 백색 LED에 원적색광의 추가는 지상부 생육특성 항목(생체중, 엽장, 엽면적)을 증대시켰고 WWFR 의 지상부 생장이 유의적으로 가장 높았다. 반면에 원적색광의 보광은 엽록소 함량을 감소시켰고 플라보노이드 지수에는 영향을 주지 않았다. 재배기간 동안의 총 소비전력은 CL 1에서 가장 낮았고 WWFR의 총 소비전력이 가장 높았다. WW와 WWFR의 광 이용효율이 높았으며 백색 LED에 원적색광의 추가는 광 이용효율을 3–15% 증대시켰다. 따라서, 백색 LED 에 원적색광의 보광은 작물의 생산성과 광 이용효율을 향상시켜 작물의 생산비용을 감소시킬 수 있었다.

Developments in cancer therapies and diagnostic techniques have improved the long-term survival of cancer patients. Certain cancer treatments, such as radiotherapy, often harm normal tissue as well as the specifically targeted cancer cells. High doses of radiation induce bone loss. This study investigated the effects of pentoxifylline (PTX) on radiation-induced bone loss in C3H/HeN mice. C3H/HeN mice were divided into sham and irradiation (3 Gy, gamma-ray, IR) groups. The irradiated mice were treated for 12 weeks with vehicle, PTX (p.o.) or PTX (s.c.). Grip strength, uterus weight, serum alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP) level were measured. Tibiae were analyzed using micro-computed tomography. There were no significant differences in the degree of grip strength, body weight and uterine weight between IR group and PTX-treated group. Treatment of PTX significantly preserved trabecular bone volume, trabecular number, trabecular separation and bone mineral density of proximal tibia metaphysic. The administration of PTX lowered serum TRAP in IR mice, suggesting that PTX can reduce the bone resorptive rate in mice. Our experimental data support the protective role of PTX against bone loss in irradiated mice. Based on the findings of this study, development of PTXbased treatments is anticipated to address bone loss after radiotherapy. Prospective dose escalation studies are required to determine the appropriate dosage of PTX.

Celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, was approved as a non-steroidal anti-inflammatory drug (NSAID), and this therapeutic application has been expanded to several other diseases, including colon cancer. Notably, a treatment strategy combining the use of celecoxib and radiation therapy has been employed for improving the control of local cancers. In this study, we examined the effect of celecoxib on irradiation-induced intestinal damage. The twenty four mice (BALB/c) were divided into four groups; 1) sham-irradiated control group, 2) celecoxib-treated group, 3) irradiated group, and 4) celecoxib-treated irradiation group. Mice were orally administered celecoxib at a dose of 25 mg/kg in a 0.1 mL volume, daily for 4 days after irradiation exposure (10 Gy). Then, histological examinations of the jejunal villous height, crypt survival, and crypt size were performed. The expression of COX-2 after administration of celecoxib in irradiated mice was examined by employing immunohistochemistry, Western blotting, and qPCR analysis. The jejunal villi height and the crypt survival were reduced in the irradiation group compared with the sham-irradiated group. Celecoxib treatment in irradiation mice even more decreased those indicators. Crypt size was increased in the radiation group compared to the sham-irradiated control group, whereas the size was decreased in the celecoxibtreated irradiation group compared with the group exposed to the radiation injury. COX-2 expression was detected in the crypt of the small intestine, and COX-2 expression was increased in the crypt lesion following radiation exposure. However, COX-2 expression was reduced in the celecoxib-treated irradiation group. Therefore, in the present study, we confirmed that celecoxib treatment after irradiation aggravated the irradiation-induced intestinal damage. These results suggest that a caution need to be administered when celecoxib treatment is performed in combination with radiation therapy for cancer treatment.